Remepy

Company Overview

Snapshot

Founded in December 2021 by Or Shoval, Michal Tsur, and Shahar Shelly, Remepy operates with 51–200 employees. The company has raised $25 million across 4 funding rounds from 10 investors. In April 2026, Remepy announced a collaboration with Merck KGaA to advance hybrid drugs across various therapeutic areas.

Business overview

Remepy is a Health Tech & Life Sciences company pioneering hybrid drugs and redefining combination therapy to bring personalized care to patients. The company's core technology involves Digital Molecules, which are mobile applications designed for hybrid drug experiences, each containing a unique digital treatment protocol. These Digital Molecules include digitized, standardized, evidence-based interventions aimed at enhancing brain plasticity and connectivity, balancing the immune system, and driving behavioral changes. Remepy addresses disease endpoints, side effects, and comorbidities, partnering with pharmaceutical companies to combine its Digital Molecules with traditional drug components. The company operates in the Digital Healthcare and Pharma & Medical Biotechnology sectors, focusing on drug discovery and development, and serves the United States market.

Strategic signal

In May 2026, Remepy reported strong Phase IIa clinical trial results for Hybridopa, a novel Hybrid Drug designed for Parkinson's disease. This successful clinical outcome provides significant validation for Remepy's hybrid drug platform, signaling to investors and the pharmaceutical industry the potential for a new class of therapeutics that combine digital interventions with traditional drug components, particularly in neurodegenerative diseases.

Company Intelligence Q&A

What is Remepy's core focus?

Remepy is focused on pioneering hybrid drugs, which combine digital treatment protocols delivered via mobile applications with traditional drug components, aiming to redefine combination therapy for personalized patient care.

What significant clinical trial results did Remepy announce recently?

In May 2026, Remepy announced strong Phase IIa clinical trial results for Hybridopa™, its first-in-class hybrid drug developed for Parkinson's disease.

Which major pharmaceutical company is Remepy collaborating with?

In April 2026, Remepy announced a collaboration with Merck KGaA, Darmstadt, Germany, to advance hybrid drugs across various therapeutic areas.

When did Remepy raise its Seed funding round?

Remepy raised a Seed funding round in May 2024, with NFX Capital leading the round and Vine Ventures also participating.

What was a key development regarding Remepy's board in early 2024?

In February 2024, former Israeli Prime Minister Naftali Bennett joined Remepy's Board for its hybrid drug endeavor, though he later departed the board in April 2026.